In a nutshell This study examined the use of nivolumab (Opdivo) in patients with heavily pretreated Hodgkin lymphoma. The authors concluded that nivolumab was effective and safe in these patients. Some background PD-1 is a protein that slows the immune response. Many cancer cells use the PD-1 pathway to block the immune system from attacking...
Read More
In a nutshell This trial examined the longer-term effectiveness of brentuximab vedotin (Adcetris) after stem cell transplant in patients with relapsed or refractory (did not respond to treatment) Hodgkin lymphoma. The authors concluded that patients who respond to brentuximab vedotin can achieve long-term disease control. Some background...
Read More
In a nutshell This study examined the safety and effectiveness of the chemotherapy ESHAP in Hodgkin lymphoma that had relapsed (returned), or that had not responded to treatment. This study concluded that ESHAP was safe and effective in these patients. Some background Hodgkin lymphoma is often curable. Some patients do not respond to treatment, or...
Read More
In a nutshell The authors aimed to summarize the results of two clinical trials to determine the effectiveness of alectinib as treatment for ALK-mutation positive NSCLC that has progressed beyond crizotinib. They concluded that alectinib is a suitable drug to treat this patient population. This treatment was FDA approved in 2015. Some...
Read More
In a nutshell This review summarized evidence on emerging immunotherapies for prostate cancer. Authors concluded that immunotherapeutic agents show promising early results in patients with advanced prostate cancer and few symptoms. Some background Immunotherapies are currently under investigation as possible cancer treatments. Immunotherapies...
Read More
In a nutshell This phase 2 trial aims to compare the benefit of two types of exercise for men with metastatic castration-resistant prostate cancer. The main outcome to be investigated is the safety of the exercises and its effect on cancer pain. The trial is recruiting in San Francisco (California). The details Metastatic castration-resistant...
Read More
In a nutshell This study examined the safety and effectiveness of radium-223, alone or in combination with other therapies, in treating metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that radium-223 was well tolerated and can be safely combined with additional therapies. Combined therapies were associated with improved...
Read More
In a nutshell This study compared the safety and effectiveness of afatinib (Gilotrif) and erlotinib (Tarceva) as second-line treatments for advanced squamous cell carcinoma (SCC). Authors reported improved survival and disease progression with afatinib compared to erlotinib. Both treatments were associated with a good safety profile. Some background...
Read More
In a nutshell This study examined the link between circulating tumor cells (CTCs) and treatment outcome in metastatic castration-resistant prostate cancer (mCRPC). Authors reported better survival outcomes for mCRPC patients with a significant decline in CTC count during treatment. Some background Metastatic castration-resistant prostate...
Read More
In a nutshell This study examined whether switching steroid drugs during secondary hormone therapy with abiraterone (Zytiga) improves treatment response in progressing, advanced prostate cancer. Researchers concluded that a steroid switch can be effective in delaying disease progression in some men. Some background Abiraterone is a secondary...
Read MoreIn a nutshell This phase 2 trial aims to evaluate combinations of hormone therapies, a steroid drug, an immunotherapy drug, and chemotherapy in the treatment of metastatic castration-resistant prostate cancer. The main outcome to be investigated is overall survival (time from treatment until death from any cause). The trial is recruiting in Houston,...
Read More
In a nutshell This review examined the effects of different radiopharmaceuticals in reducing bone pain in advanced prostate cancer. Researchers concluded that radiopharmaceuticals were associated with a significant reduction in bone pain. Some background When prostate cancer spreads outside of the prostate (also called metastatic prostate cancer),...
Read More
